The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Obinutuzumab plus len promising in untreated FL
Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, discusses the results of the phase II trial (NCT01582776) of obinutuzumab, a monoclonal antibody glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC), with lenalidomide in previously untreated, high tumor burden follicular lymphoma (FL). This drug combination was associated with high complete response and manageable toxicities. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
